Nuvation Bio registers Phase 2 trial of safusidenib for IDH1-mutant glioma after vorasidenib failure

Nuvation Bio's registry activity for the week centers on a single new trial listing.

• Nuvation Bio registered a Phase 2 study (NCT07703436) of safusidenib erbumine in patients with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib confirmed by Blinded Independent Central Review per modified Response Assessment in Neuro-Oncology 2.0, and are not in need of immediate chemotherapy or radiotherapy.¹ The study plans to enroll 40 participants (estimated)¹ and lists its primary outcome as Objective Response Rate per modified Response Assessment in Neuro-Oncology 2.0 assessed by Blinded Independent Central Review, measured from first dose until first documented disease progression, approximately 18 months.¹ The record shows an estimated start of 2027-03 (estimated)¹ and lists sites including University of California, Los Angeles, University of California, San Francisco, and Yale University, all currently not yet recruiting¹.